WYE 132 MTOR Inhibitors WYE 125132 Cas 1144068-46-1
WYE 132 MTOR Inhibitors WYE 125132 Cas 1144068-46-1
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:WYE-125132 |
Purity:98% min |
|
CAS NO:1144068-46-1 |
Solubility:DMSO150 mg/mL |
|
Molecular Formula:C27H33N7O4 |
Package:Package according to customer requirements |
|
Molecular Weight:375.399 |
Storage:Store at -20℃ |
Quality control
Remarks
WYE-125132, also known as WYE-132, is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor (IC(50): 0.19 +/- 0.07 nmol/L; >5,000-fold selective versus PI3Ks). WYE-132 inhibited mTORC1 and mTORC2 in diverse cancer models in vitro and in vivo. Importantly, consistent with genetic ablation of mTORC2, WYE-132 targeted P-AKT(S473) and AKT function without significantly reducing the steady-state level of the PI3K/PDK1 activity biomarker P-AKT(T308), highlighting a prominent and direct regulation of AKT by mTORC2 in cancer cells.
Related Products
Capmatinib; MK-8033; Merestinib; SGX-523; MDK-0264; Tepotinib; NPS-1034; PHA-665752; SCR-1481B1; SU11606
References
[1].Yu K, et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.Cancer Res. 2010 Jan 15;70(2):621-631.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.